GH-axis research
GHRP-6
Lyophilized endocrine-signaling research peptide for systems review
GHRP-6 is an early growth hormone releasing peptide used as a reference point in GH secretagogue literature.
Support can confirm any currently available COAs or batch documentation for this product.
Request available documentsConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesFor laboratory research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, mitigate, or prevent disease.
Keep sealed, cold, dry, and protected from heat swings. Confirm product-specific storage on arrival.
Packed for transit stability with order support available for warm-weather routes.
Batch-linked certificate support is available through the documentation desk.
Research context
GHRP-6 research profile
GHRP-6 is an early synthetic growth hormone-releasing peptide used as a reference in ghrelin-receptor and GH-secretagogue research. Experimental studies measure GH response, receptor signaling, endocrine markers, appetite-related pathways, and differences from GHRP-2, ipamorelin, hexarelin, or GHRH analogs. It is commonly chosen when a project needs a historically established GHS-R comparator with a broad physiological research record. Because secretagogues can differ in selectivity and off-target endocrine observations, compounds should not be treated as interchangeable. Findings from older human or animal studies describe their specific materials and protocols and do not establish the suitability or performance of a separate catalog product.
Molecular class
Six-residue GH secretagogue
Sequence / composition
His-D-Trp-Ala-Trp-D-Phe-Lys-NH2; a hexapeptide containing D-tryptophan and D-phenylalanine.
Research design note
Its historical GHS-R profile makes direct comparison with newer secretagogues a frequent research use case.
Proposed mechanism
A synthetic GHS-R1a agonist that stimulates growth-hormone release and activates central ghrelin-related appetite pathways. It also has measurable endocrine activity beyond GH in some models.
Effects reported in studies
- Human and animal studies reported acute GH release and increased food intake or appetite-related signaling.
- Some studies observed increases in cortisol or prolactin, demonstrating lower endocrine selectivity than a purely GH-specific ligand.
- Responses can diminish or change with repeated exposure and depend on endogenous GHRH and somatostatin tone.
Common research endpoints
GHS-R activation, GH, ACTH, cortisol, prolactin, food intake, hypothalamic signaling, glucose, receptor desensitization, and interaction with GHRH.
Evidence and limitations
The acute endocrine and appetite-related effects are documented in preclinical and human pharmacology studies. Long-term safety and product equivalence remain unestablished.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
Where can I find product documentation?
Contact support with the product name and any relevant order or batch reference to request available documents.
How can I compare pack options?
Where multiple pack sizes are available, Azure shows the price per listed vial so you can compare catalog value directly.